Page 57 - Approval Program News Today

These are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.

After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.

Cyber and physical threats against commercial satellites are no longer a hypothetical discussion. Russia has demonstrated intent and capability to attack

Sarah Silbiger/Getty Images, FILE(WASHINGTON) -- A congressional investigation into the Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug with inconsistent data. Aduhelm is notable for being the first drug in recent years approved to treat the underlying cause of Alzheimer's, a disease with no known cure that is characterized by progressive dementia that aff...

The approval of an Alzheimer's treatment may not have followed standard approval procedures, according to an 18-month investigation by the House Oversight and Reform Committee.

The Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug.

Aman Khera and Dr Christine Moore of Worldwide Clinical Trials share how regulatory agencies are supporting psychedelic research.

Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.

Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.

Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.